Agreement, Initial Term

No definition available.

Name:	bhvn_AgreementInitialTerm
Namespace Prefix:	bhvn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Eligible Milestone Payments, Commercial

+ References

No definition available.

+ Details

Name:	bhvn_EligibleMilestonePaymentsCommercial
Namespace Prefix:	bhvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Eligible Milestone Payments, Development

+ References

No definition available.

+ Details

Name:	bhvn_EligibleMilestonePaymentsDevelopment
Namespace Prefix:	bhvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=bhvn_ModaPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bhvn_ModaAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Moda Pharmaceuticals LLC (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 01, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
License and other agreements
Research and development		$ 79,490,000	$ 177,087,000	$ 142,951,000	$ 247,183,000
Moda Pharmaceuticals LLC
License and other agreements
Research and development		$ 0	$ 0	$ 0	$ 0
Moda Pharmaceuticals LLC \| Moda Agreement
License and other agreements
Eligible development milestone payments	$ 81,612,000
Eligible commercial milestone payments	$ 30,171,000
Initial term of agreement (in years)	4 years
Moda Pharmaceuticals LLC \| Moda Agreement \| License agreement
License and other agreements
Payment for license agreement	$ 2,700,000
Issuance of common shares as payment for assets (in shares)	37,836
Issuance of common shares as payment for assets	$ 3,243,000